Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
1J5.SI
Strong BuyFull HouseFLAGHyphens Pharma International Limited · Healthcare · Singapore · $86M · Avg Vol: $53K/d
Hyphens Pharma has defensive characteristics and recent insider support, but the market cap is small ($111M), limiting liquidity for a global fund. While the business model is solid, the thesis lacks the dramatic macro tailwind needed to justify high-conviction status over larger, more liquid compounders.
COMPANY DESCRIPTION
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally.
FINANCIAL SUMMARY (SGD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 162.3M | 170.6M | 195.4M | 177.4M | 3.0% | 176.7M | 185.1M | 199.5M | 6.1% |
| EPS (SGD) | 0.02 | 0.04 | 0.03 | 0.03 | 0.02 | -4.5% | 0.03 | 0.04 | 0.04 | 51.9% |
| Shares | — | 308.8M | 309.2M | 308.9M | 308.9M | +0.0% | 308.9M | — | — | — |
| Debt | — | 5.7M | 6.8M | 14.1M | 9.4M | 18.5% | 11.1M | — | — | — |
| Equity | — | 69.0M | 63.0M | 70.9M | 70.1M | 0.5% | — | — | — | — |
| Op CF | — | 16.9M | 5.6M | 60.0K | 18.7M | 3.6% | 20.7M | — | — | — |
| Inv CF | — | -1.0M | -1.5M | -3.1M | -4.6M | — | — | — | — | — |
| Fin CF | — | 1.1M | -17.3M | 3.1M | -10.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1J5.SI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1J5.SI | Hyphens Pharma International Limited(you) | $86M | 100 | Strong Buy |
| 5WA.SI | OUE Healthcare Limited | $167M | 88 | Strong Buy |
| AP4.SI | Riverstone Holdings Limited | $901M | 94 | Strong Buy |
| ULG.SI | UltraGreen.ai Limited | $771M | 89 | Strong Buy |
| QC7.SI | Q & M Dental Group (Singapore) Limited | $402M | 61 | Hold |
| BSL.SI | Raffles Medical Group Ltd | $1.2B | 77 | Buy |
| 1D4.SI | Aoxin Q & M Dental Group Limited | $196M | 39 | Hold |
| FHH.SI | Foundation Healthcare Holdings Limited | $751M | 58 | Hold |
| 42C.SI | iX Biopharma Ltd. | $347M | 35 | Hold |
| BMGL | Basel Medical Group Ltd | $122M | 3 | Strong Sell |
Peer medians: ROE 1.2% · P/E 21.4x · Gross margin 42.3%